🇺🇸 FDA
Pipeline program

AMX0035

AMX-8000

Phase 2 small_molecule completed

Quick answer

AMX0035 for Alzheimer Disease is a Phase 2 program (small_molecule) at Amylyx Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Amylyx Pharmaceuticals
Indication
Alzheimer Disease
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials